The scholarly study results, which represent an additional five months of follow-up, were shown at the 2011 CTRC-AACR San Antonio Breasts Malignancy Symposium , abstract #S3-7. Concurrently, initial results of BOLERO-2 were published today in The New England Journal of Medication and were initial presented at the 2011 European Multidisciplinary Cancer Congress . ‘These data provide longer-term proof the benefit of adding everolimus to hormonal therapy in sufferers whose disease progressed while on or following preliminary hormonal treatment, representing a major paradigm shift in the administration of ER+HER2 – breast malignancy,’ said Gabriel Hortobagyi, MD, Chair of Breasts Medical Oncology, University of Texas MD Anderson Cancer Center and lead research author.The amount of patients who knew the real amount of polyps found throughout their process was about 39 %, ten %, 7 % and 6 %, respectively. ‘Individuals’ personal recollections of endoscopy results can be misleading,’ said study author Dr. Amer Alame, a colorectal doctor at St. John Hospital and INFIRMARY in Detroit. In an ACS news discharge, he said it is important for doctors to repeat important info to patients after a colonoscopy, including what was done, the effects and recommendations for follow-up care.